🔍

Morepen Laboratories Limited (MOREPENLAB)

₹123.87 -1.38% last close, 16 Oct

📊 NSE: MOREPENLAB 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📢 Latest filing: 14 Oct 2026 📝 Analysis written: 14 Dec 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Morepen Laboratories' revenue was ₹570 Cr (+34.1% year on year, +17.6% on the previous quarter), and net profit ₹56.3 Cr (+394.0% year on year); the operating margin was 14.5%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹570	+34.1%	+17.6%
Operating profit	₹82.5	+241.5%	+243.9%
Net profit	₹56.3	+394.0%	+252.2%
EPS (₹)	1.03	+415.0%	+255.2%
Operating margin	14.5%	—	—

Full quarterly financials → Results calendar →

MOREPENLAB exchange data

NSE end-of-day data for Fri, 16 Oct 2026

It closed at a price band (circuit) on 2 sessions in about the last 20.

₹123.87NSE close · -1.38%

Delivery in the last 5 sessions: 26.1% · 34.2% · 30.4% · 41.6% · 37.4%

Circuit stocks →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Himachal HC Quashes Rs 117.94 Cr GST Demand Show Cause Notice Against Morepen Laboratories

🟢 POSITIVE ⭐ 7/10

LEGAL 📅 14 Oct 2026, 06:21 PM

The High Court of Himachal Pradesh has quashed a Show Cause Notice (SCN) issued by the Central GST Commissionerate demanding Rs 117.94 crore in excess GST refund along with interest and penalty. The original demand dated December 2, 2025, represented approximately 83.6% of the company's TTM PAT of Rs 141 crore and 9.5% of its net worth (Rs 1,243 crore). With the writ petition disposed in favour of Morepen Laboratories, the company faces no financial liability or operational disruption from this dispute. The order was passed on October 12, 2026, and received by the company on October 14, 2026.

Himachal Pradesh High Court quashed the GST Show Cause Notice demanding recovery of Rs 117,94,03,452
Demand amount of Rs 117.94 crore represents ~83.6% of TTM PAT (Rs 141 crore) and ~6% of TTM revenue (Rs 1,951 crore)
Allegations pertained to excess GST refund claims under Section 54 of CGST Act read with Rule 89(4)
Order passed on October 12, 2026, and formally received by the company on October 14, 2026 at 3:00 p.m.
Company confirmed zero financial, operational, or other adverse impact following the court ruling

💡 Track whether the GST Department files an appeal or Special Leave Petition (SLP) before the Supreme Court against the High Court order, and monitor upcoming Q2 FY27 earnings for core operating performance.

Morepen Labs Submits First U.S. ANDA for Sitagliptin Tablets Targeting DPP-4 Diabetes Market

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 28 Sep 2026, 08:56 AM

Morepen Laboratories has filed its first Abbreviated New Drug Application (ANDA No. 221758) with the U.S. FDA for Sitagliptin Tablets USP in 25 mg, 50 mg, and 100 mg strengths. The innovator brand, Januvia, recorded global sales of approximately US$1.604 billion in 2025. The company projects an approval and commercialization timeline of 24–36 months, subject to FDA review and facility inspections. This filing marks Morepen's transition from an API-focused player to an integrated CDMO and finished dosage manufacturer.

First U.S. ANDA submitted on September 25, 2026, for Sitagliptin Tablets USP in 25 mg, 50 mg, and 100 mg strengths
Innovator drug Januvia recorded worldwide sales of approximately US$1.604 billion in 2025
Key U.S. patent expires on November 24, 2026, with paediatric exclusivity ending May 24, 2027
Estimated timeline to commercial supply is 24–36 months pending regulatory approvals and inspections

💡 Track FDA acceptance of the ANDA filing for substantive review and monitor outcomes of future USFDA GMP inspections at Morepen's formulation facilities.

Morepen Labs 41st AGM: Shareholders Approve Medical Devices Slump Sale Timeline Extension

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 26 Sep 2026, 08:11 PM

Morepen Laboratories reported voting results for its 41st AGM held on September 26, 2026. All 7 resolutions were approved by shareholders, including the adoption of FY26 annual accounts, declaration of final dividend, and key leadership re-appointments. Crucially, Resolution 7 passed with 87.49% approval to extend the timeline for hiving off the Medical Devices business to subsidiary Morepen Medipath Limited via a slump sale. Public institutional investors heavily opposed Resolution 7, casting 99.37% of their votes against it, though non-institutional public votes carried the special resolution through.

Resolution 7 to extend slump sale timeline for Medical Devices hiving off passed with 87.49% votes in favour
Public institutions voted 99.37% against Resolution 7 (56.41 lakh votes against out of 56.77 lakh polled)
Sushil Suri re-appointed Chairman & MD with 99.96% overall votes in favour
Sanjay Suri elevated to Managing Director with 99.99% overall votes in favour
Total valid votes cast for the FY26 dividend resolution stood at 24.02 crore shares (99.998% in favour)

💡 Track the revised closing timeline and commercial terms for the slump sale of the Medical Devices business to Morepen Medipath Limited, especially given significant institutional dissent.

Morepen Labs Holds 41st AGM: Considers ₹0.20 Dividend, Medical Devices Business Slump Sale Extension

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 26 Sep 2026, 05:39 PM

Morepen Laboratories concluded its 41st Annual General Meeting held on September 26, 2026, with 92 members attending via video conference. Key agenda items included the adoption of FY26 financial statements and the declaration of a final dividend of ₹0.20 per share (face value ₹2). Shareholders also voted on leadership changes, including elevating Mr. Sanjay Suri to Managing Director and reappointing Mr. Sushil Suri as CMD. Additionally, approval was sought to extend the timeline for the slump sale of the Medical Devices business to its subsidiary, Morepen Medipath Limited.

AGM conducted with 92 members present through VC/OAVM
Final dividend of ₹0.20 per equity share of face value ₹2 considered for FY26
Approval sought for extending timeline to hive off Medical Devices business to Morepen Medipath Limited via slump sale
Special resolutions placed for elevating Sanjay Suri to Managing Director and reappointing Sushil Suri as Chairman & MD

💡 Track the formal scrutinizer's report for final voting results on the slump sale timeline extension and monitor the execution progress of hiving off the Medical Devices business.

CRISIL Assigns 'CRISIL ESG 60' Rating (Adequate) to Morepen Laboratories

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 22 Sep 2026, 04:16 PM

Morepen Laboratories informed exchanges that CRISIL ESG Ratings & Analytics has independently assigned an overall ESG rating of 'CRISIL ESG 60' for Fiscal 2026. This score places the company in the 'Adequate' rating category. The company clarified that it did not engage CRISIL for this assessment, which was conducted based purely on publicly disclosed information. The announcement has no direct financial or operational impact on the company's TTM revenue of ₹1,951 Cr or net profit.

Assigned overall ESG rating of 'CRISIL ESG 60' by Crisil ESG Ratings & Analytics Limited
Rating falls under the 'Adequate' rating category
Assessment was conducted independently for Fiscal 2026 based on publicly disclosed information
Company clarified that it had not engaged CRISIL for the ESG ratings

💡 Monitor whether future institutional investors use this ESG score for portfolio mandates; no immediate action is needed.

Morepen Labs Expands API & CDMO Capacity by 14.8% to 614 KL Ahead of Schedule

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 07 Sep 2026, 08:48 AM

Morepen Laboratories has completed the first phase of its manufacturing capacity expansion ahead of schedule. The company's installed reactor capacity for API and CDMO expanded from 535 KL to 614 KL, adding 79 KL of capacity (~14.8% increase). This enhanced infrastructure is aimed at scaling commercial CDMO supplies and supporting its core API portfolio against a TTM revenue base of ₹1,951 crore.

Installed reactor capacity increased from 535 KL to 614 KL (addition of 79 KL).
Represents an immediate ~14.8% expansion in API and CDMO manufacturing capacity.
First phase completed ahead of the previously indicated timeline.
Aimed at strengthening readiness for commercial CDMO contracts and core API programs.

💡 Track capacity utilization levels, subsequent phases of expansion, and CDMO revenue ramp-up in upcoming quarterly earnings releases.

Morepen Labs Dispatches FY26 Annual Report Link; Sets Record Date for ₹0.20 Dividend on Sep 19, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Sep 2026, 01:50 PM

Morepen Laboratories has dispatched letters containing the FY2025-26 Annual Report weblink and QR code to shareholders whose email addresses are not registered. The company's 41st Annual General Meeting (AGM) is scheduled for Saturday, September 26, 2026, via video conferencing. The Board has recommended a final dividend of ₹0.20 per equity share for FY26, with the record date set as September 19, 2026. Remote e-voting will be open from September 23, 2026 (9:00 AM) to September 25, 2026 (5:00 PM).

41st AGM scheduled for September 26, 2026 at 1:00 PM IST via video conferencing
Final dividend proposed at ₹0.20 per equity share for FY2025-26
Record date for dividend entitlement fixed as Saturday, September 19, 2026
Remote e-voting period runs from September 23, 2026 (9:00 AM) to September 25, 2026 (5:00 PM)

💡 Shareholders seeking dividend payout must hold shares prior to the September 19, 2026 record date and ensure bank/KYC details are fully updated with DPs or RTA.

Morepen Labs 41st AGM Notice: Declares ₹0.20 Dividend, Highlights ₹825 Cr Multi-Year CDMO Win

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 02 Sep 2026, 01:42 PM

Morepen Laboratories has issued notice for its 41st AGM scheduled for September 26, 2026, setting September 19, 2026 as the record date for a final dividend of ₹0.20 per equity share (FV ₹2). Key resolutions include the elevation of Mr. Sanjay Suri as Managing Director, re-appointment of Mr. Sushil Suri as CMD, and extending the timeline for hiving off its Medical Devices business into subsidiary Morepen Medipath Limited. The company disclosed medium-term outlook targets, citing a recently secured ₹825 crore multi-year CDMO contract (~42.3% of TTM revenue of ₹1,951 crore) aimed at supporting 15-20% annual revenue growth and 150-250 bps EBITDA margin expansion.

Final dividend of ₹0.20 per share proposed; record date set for September 19, 2026
AGM scheduled for September 26, 2026 via video conferencing, with remote e-voting from September 23 to 25, 2026
Resolutions to approve executive remuneration and re-appointments of CMD Sushil Suri and MD Sanjay Suri
Company highlights a recently secured ₹825 crore multi-year CDMO contract targeting 15-20% revenue growth and 150-250 bps EBITDA margin expansion

💡 Track voting outcomes at the AGM on September 26, 2026, and monitor the execution timeline of the ₹825 crore CDMO contract and Medical Devices hive-off.

Rs 20 Cr Investment in Wholly Owned Subsidiary Morepen RX Limited via Rights Issue

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 06 Aug 2026, 05:02 PM

Morepen Laboratories has infused Rs 20 crore into its wholly-owned subsidiary, Morepen RX Limited (MRX), by subscribing to 2 crore equity shares at par (Rs 10 each). MRX is the group's arm for sales and marketing of branded prescription products in India. This investment represents approximately 1.6% of Morepen's consolidated net worth of Rs 1,243 crore. Notably, MRX's turnover saw a sharp decline to Rs 54.50 crore in FY26 from Rs 112.76 crore in FY25, suggesting the capital infusion may be intended to stabilize operations.

Allotment of 2,00,00,000 equity shares at Rs 10 each, aggregating to Rs 20 crore.
Total shareholding in Morepen RX Limited increased to 2,70,82,356 equity shares.
MRX turnover for FY26 reported at Rs 54.50 crore, a 51.6% decrease from FY25's Rs 112.76 crore.
MRX net worth stood at a marginal Rs 47.72 lakh as of March 31, 2026, prior to this infusion.
The subsidiary was incorporated recently on March 17, 2023.

💡 Investors should monitor the recovery of the branded prescription (Rx) segment, as the subsidiary's revenue halved in the last fiscal year despite the parent's overall growth strategy.

Morepen Lab Q1 Net Profit jumps 570% YoY to ₹54 Cr; Medical Devices hive-off timeline extended

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 04 Aug 2026, 02:36 PM

Morepen Laboratories reported a robust Q1 FY27 with consolidated net profit surging to ₹53.99 Cr, compared to ₹8.06 Cr in Q1 FY26. Revenue for the quarter grew 38% YoY to ₹546.35 Cr, significantly exceeding the previous year's quarterly average. The board also approved the re-appointment of Sushil Suri as CMD for three years and extended the timeline for hiving off the Medical Devices business into a subsidiary. A record date of September 19, 2026, has been set for the final dividend.

Consolidated Net Profit for Q1 FY27 rose to ₹53.99 Cr from ₹8.06 Cr in the year-ago period
Total Income increased to ₹546.35 Cr in Q1 FY27, representing a 38% growth over Q1 FY26
Record date for the FY26 final dividend is set for September 19, 2026
CMD Sushil Suri re-appointed for a 3-year term effective October 20, 2026
Timeline extended for the slump sale of the Medical Devices business to Morepen Medipath Limited

💡 Watch for the completion of the Medical Devices hive-off and whether the Q1 margin improvement is sustainable against Chinese API pricing pressure.

Morepen Labs Q1 Net Profit Jumps 570% YoY to ₹54 Cr; CMD Re-appointed for 3 Years

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 04 Aug 2026, 02:20 PM

Morepen Laboratories reported a robust performance for Q1 FY27, with consolidated net profit surging to ₹53.99 Cr from ₹8.06 Cr in the year-ago period. Total revenue grew 38% YoY to ₹546.35 Cr, driven by strong operational performance. The board has approved the re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a three-year term starting October 2026. Additionally, the company set September 19, 2026, as the record date for the FY26 final dividend and extended the timeline for hiving off its Medical Devices business.

Consolidated Net Profit increased by 569.8% YoY to ₹53.99 Cr in Q1 FY27
Total Revenue from operations rose 38.1% YoY to ₹546.35 Cr compared to ₹395.38 Cr
Mr. Sushil Suri re-appointed as CMD for a 3-year term effective from October 20, 2026
Record date for final dividend (FY26) fixed as September 19, 2026
Timeline extended for the slump sale of the Medical Devices business into Morepen Medipath Limited

💡 Investors should monitor the upcoming 41st AGM on September 26, 2026, for shareholder approval of the CMD re-appointment and the Medical Devices business restructuring.

Morepen Lab Q1 Net Profit Jumps 569% to ₹53.99 Cr; Dividend Record Date Set for Sept 19

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 04 Aug 2026, 02:12 PM

Morepen Laboratories reported a robust Q1 FY27 with consolidated net profit surging to ₹53.99 Cr, a 569% increase from ₹8.06 Cr in the year-ago period. The Board has fixed September 19, 2026, as the record date for the final dividend of FY26, pending shareholder approval. Additionally, the company extended the timeline for hiving off its Medical Devices business into a subsidiary, Morepen Medipath Limited, to streamline operations. Chairman & Managing Director Sushil Suri has been re-appointed for a further three-year term effective October 2026.

Consolidated Net Profit for Q1 FY27 reached ₹53.99 Cr, significantly exceeding the ₹8.06 Cr reported in Q1 FY26.
Profit Before Tax (PBT) for the quarter stood at ₹72.15 Cr compared to ₹11.35 Cr in the corresponding previous quarter.
Record date for the final dividend is confirmed as September 19, 2026, with the AGM scheduled for September 26, 2026.
Re-appointment of Mr. Sushil Suri as CMD approved for a 3-year tenure from October 20, 2026, to October 19, 2029.
Extension granted for the slump sale of the Medical Devices business, which the company aims to scale to 45% of total revenue.

💡 Investors should monitor the execution of the Medical Devices business hive-off and the margin sustainability in the API segment given the 569% profit jump. Watch for the 41st AGM outcomes on September 26 for final dividend approval.

394% PAT Growth: Morepen Labs reports record Q1 FY27 revenue and CDMO commercialization

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 04 Aug 2026, 02:06 PM

Morepen Laboratories reported its highest-ever quarterly performance in Q1 FY27, with revenue growing 34% YoY to Rs 575.31 Cr. Profitability saw a massive surge, with PAT increasing 394% YoY to Rs 56.35 Cr and EBITDA margins expanding significantly to 15.25% from 6.65% YoY. A major strategic milestone was reached as the company's Rs 825 Cr CDMO mandate entered full-scale commercialization, contributing Rs 58 Cr in dispatches during the quarter. The company also maintained a clean regulatory record with its fourth consecutive USFDA inspection resulting in zero observations.

Quarterly PAT surged 394% YoY to Rs 56.35 Cr, which is approximately 58% of the total PAT recorded in the entire previous fiscal year (FY26).
Revenue reached a record Rs 575.31 Cr, driven by a 111% growth in export revenue and a 31% growth in the API segment.
EBITDA grew by 207% YoY to Rs 87.72 Cr, with margins improving by 860 basis points to 15.25%.
The Rs 825 Cr CDMO mandate has commenced commercialization, with Rs 58 Cr worth of supplies completed in Q1 FY27.
API exports grew 42% YoY, while the Medical Devices segment continued to scale with 19% growth.

💡 Investors should monitor the quarterly execution rate of the remaining ~Rs 767 Cr CDMO mandate and the progress of the phased capacity expansion to 1,200 KL by FY30.

Rs 575 Cr Revenue & 394% PAT Growth: Morepen Labs Q1 FY27 Performance

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 04 Aug 2026, 02:01 PM

Morepen Laboratories reported a strong Q1 FY27 with revenue growing 34% YoY to Rs 575.31 Cr. The company achieved significant margin expansion, with EBITDA rising 207% to Rs 87.72 Cr and PAT surging 394% to Rs 56.35 Cr. This performance was driven by the commercialization of a large Rs 825 Cr CDMO mandate, which contributed Rs 58 Cr in dispatches this quarter. Additionally, the company is executing a major capacity expansion, aiming to double its API capacity from 600 KL to 1200 KL by FY30.

Quarterly revenue reached a record Rs 575.31 Cr, representing a 34% YoY growth.
PAT increased by 394% YoY to Rs 56.35 Cr, driven by operating leverage and a better product mix.
EBITDA margins expanded significantly to 15.25% from 6.65% in the previous year's quarter.
Commenced commercial supplies for a Rs 825 Cr CDMO mandate, with Rs 58 Cr dispatched in Q1.
API capacity expansion roadmap targets an increase from 600 KL to 1200 KL by FY30, with Phase-1 (1000 KL) expected by Q4 FY26.

💡 Investors should monitor the ramp-up of the remaining Rs 767 Cr CDMO mandate and the timely completion of the Phase-1 capacity expansion to 1000 KL by Q4 FY26.

Morepen Lab Q1 Net Profit Jumps 570% YoY to ₹53.99 Cr; Medical Device Hive-off Timeline Extended

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 04 Aug 2026, 01:50 PM

Morepen Laboratories reported a robust Q1 FY27 with consolidated net profit surging to ₹53.99 Cr from ₹8.06 Cr in the same quarter last year. Total revenue for the quarter grew 38.2% YoY to ₹546.35 Cr, significantly outpacing the previous year's performance. The board has set September 19, 2026, as the record date for the final dividend and extended the timeline for hiving off its medical devices business into a subsidiary. Additionally, Chairman Sushil Suri has been re-appointed for a three-year term starting October 2026.

Consolidated Net Profit increased by 569.8% YoY to ₹53.99 Cr in Q1 FY27
Total Income for the quarter rose 38.2% to ₹546.35 Cr compared to ₹395.38 Cr in Q1 FY26
Basic EPS improved significantly to ₹0.99 from ₹0.15 in the year-ago period
Record date for final dividend (FY26) confirmed as September 19, 2026
Timeline extended for hiving off the Medical Devices Business into Morepen Medipath Limited via slump sale

💡 Investors should monitor the upcoming 41st AGM on September 26, 2026, for formal approval of the medical device business restructuring and the re-appointment of the CMD. The sharp margin improvement in Q1 warrants a close look at the sustainability of product realizations in the API segment.

View All MOREPENLAB Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company reported a marginal Total Operating Income (TOI) growth of 1.10% to INR 1,554.54 Cr in FY2025. Segment performance was mixed: Generics grew by 50% to INR 128.46 Cr, Institutional Supplies grew by 14.52% to INR 49.52 Cr, and Formulations grew by 3.90% to INR 138.69 Cr. API volumes increased 8.4% to 465 MT, but revenue was offset by an 8.1% decline in average realization from INR 21,886 to INR 20,111 per unit.

Geographic Revenue Split

Morepen exports to more than 80 countries, with recent growth driven by enhanced market penetration and customer acquisition in the European market. The company is also expanding its footprint through a Dubai-based subsidiary to target new international markets.

Profitability Margins

Profitability faced headwinds in FY2025; Operating Profit Margin declined from 10.52% to 9.87% and Net Profit Margin dropped from 7.16% to 6.47%. This compression was primarily due to escalating raw material costs in the API and home health segments and falling realizations in the API business.

EBITDA Margin

EBITDA margin stood at 9.87% in FY2025, a decrease of 65 basis points from 10.52% in FY2024. EBITDA absolute value fell 5.2% to INR 153.41 Cr from INR 161.82 Cr, reflecting the impact of intense pricing competition from Chinese manufacturers and higher input costs.

Capital Expenditure

The company raised INR 200 Cr through a Qualified Institutional Placement (QIP) to fund expansion. A significant portion is allocated to the high-growth medical devices segment, which is projected to contribute up to 45% of total revenue in the future. Actual QIP-related expenses were INR 10.92 Cr, lower than the projected INR 12.85 Cr.

Credit Rating & Borrowing

Infomerics assigned a long-term rating of 'IVR A-/Stable' in August 2025. The company maintains a low overall gearing of 0.09x and a Debt Equity Ratio of 0.07. Average fund-based working capital utilization is low at ~49%, indicating a strong liquidity buffer and low borrowing costs.

⚙️ Operational Drivers

Raw Materials

Key raw materials include API intermediates and components for home health devices (glucometers/BP monitors). Raw material costs are a critical component, and recent increases in these inputs led to negative inventory adjustments and margin pressure.

Import Sources

The company is exposed to volatility in both domestic and imported inputs. While specific countries are not listed for all inputs, the API segment faces significant competitive pressure and pricing dynamics influenced by Chinese manufacturers.

Key Suppliers

Not specifically disclosed in the available documents; however, the company is shifting away from low-margin third-party manufacturing to focus on in-house manufacturing capacities.

Capacity Expansion

API production capacity utilization is increasing, with production rising 10.7% from 448 MT in FY2024 to 496 MT in FY2025. The company is also expanding its medical device manufacturing complex in Baddi, which houses 10 specialized plants.

Raw Material Costs

Raw material costs increased in FY2025, particularly in the API and home health segments. While the company has mechanisms to pass on costs, a time lag in price adjustments typically exposes margins to interim pressure.

Manufacturing Efficiency

The company is focusing on better utilization of in-house manufacturing capacities to promote a stronger mix of high-margin trade and institutional sales.

Logistics & Distribution

The company distributes to over 80 countries and has a wide domestic reach for its 'Dr. Morepen' brand, which has sold over 12 million glucometers to date.

📈 Strategic Growth

Expected Growth Rate

9.30%

Growth Strategy

Growth will be achieved by scaling the medical devices segment to 45% of revenue, expanding the 'Dr. Morepen' consumer brand, and increasing direct institutional sales. The company is also investing in new-generation APIs (3.5-4 year development cycle) and expanding internationally via its Dubai subsidiary.

Products & Services

Active Pharmaceutical Ingredients (Montelukast, Loratadine), medical devices (glucometers, blood pressure monitors, thermometers), finished formulations, and the Dr. Morepen Sync App for health monitoring.

Brand Portfolio

Dr. Morepen, Morepen Rx.

New Products/Services

Launched the Dr. Morepen Sync App to monitor vital health metrics. New generation APIs are under development with a 3.5 to 4-year timeline to reach commercial production.

Market Expansion

Targeting the European market through enhanced customer acquisition and exploring new global territories via a Dubai-based subsidiary.

Market Share & Ranking

Global leadership in the production of Montelukast and Loratadine APIs. Over 12 million glucometers sold in India, indicating a leading position in the home health segment.

Strategic Alliances

The company realigned its business by transferring brand-sharing operations to its subsidiary, Dr. Morepen Limited, to streamline focus.

🌍 External Factors

Industry Trends

The industry is shifting toward digital health (e.g., Sync App) and increased domestic manufacturing of medical devices. Morepen is positioning itself as an integrated player across APIs, devices, and formulations to capture this 10-15% sectoral growth.

Competitive Landscape

Faces intense competition from large-scale Chinese API manufacturers and domestic pharmaceutical players in the formulations and generics space.

Competitive Moat

Moat is built on a 40-year legacy, USFDA/WHO-GMP certified manufacturing, and the strong 'Dr. Morepen' brand equity in the Indian consumer healthcare market. Sustainability depends on successfully transitioning from legacy APIs to new-generation products.

Macro Economic Sensitivity

Sensitive to global pharmaceutical demand and raw material price cycles. Profitability is highly correlated with the cost of API intermediates.

Consumer Behavior

Increasing proactive health management by consumers is driving demand for home-use medical devices like glucometers and BP monitors.

Geopolitical Risks

Trade dynamics with China significantly impact the API segment's pricing and margin profile.

⚖️ Regulatory & Governance

Industry Regulations

Highly regulated by USFDA, WHO-GMP, EU-GMP, TGA (Australia), and Anvisa (Brazil). Adherence to these international standards is mandatory for maintaining export market access.

Environmental Compliance

Operates under WHO-GMP and EU-GMP standards which require stringent environmental and quality controls at the Baddi manufacturing complex.

Taxation Policy Impact

The company is subject to standard Indian corporate tax rates; however, it is currently contesting a GST refund issue.

Legal Contingencies

Received a Show Cause Notice (SCN) on December 3, 2025, from the Central GST Commissionerate, Shimla, regarding an ITC refund claim for FY2020 to FY2024. The dispute involves the application of Rule 89(4) vs Rule 89(4B) of the CGST Rules.

⚠️ Risk Analysis

Key Uncertainties

Margin compression in the API segment (currently the largest revenue share) due to falling realizations and escalating costs remains the primary risk to earnings.